LDL-cholesterol goals and changes in C reactive protein in high coronary risk patients;Objetivos terapéuticos del colesterol LDL y cambios de la proteína C reactiva en pacientes de alto riesgo coronario

Revista Clinica Espanola

Volumn 209, Issue 9, 2009, Pages 415-423

  Costa, J A ^a   Rodilla, E ^a,b   Perez Lahiguera F ^a,b   Miralles, A ^a   Gonzalez C ^a   Pascual, J M ^a,b,c  

^a HOSPITAL DE SAGUNTO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

C reactive protein; Ezetimibe; High coronary risk; statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DISORDERS OF CHOLESTEROL METABOLISM; DRUG DOSE REGIMEN; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL;

AGED; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350757757     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(09)72513-5     Document Type: Article

References (25)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278 [Errata, Lancet 2005;366:1358, 2008; 371: 2084]
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third Report of the National Cholesterol Education Program in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. Grundy S.M., Cleeman Jl., Bairey Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
5. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al., For the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial, Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
6. Gómez Belda A., Rodilla E., Albert A., García L., González C., and Pascual J.M. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc) 121 (2003) 527-531
7. García Ruiz F.J., Marín Ibáñez P., Pérez Jiménez F., Pinto X., Nocea G., Ahumada C., et al. Current lipid managment and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmaeconomics 22 Suppl 3 (2004) 1-12
8. Gómez Belda A., Rodilla E., González C., Costa J.A., Serra B., and Pascual J.M. Objetivos del tratamiento hipolipemiante en pacientes con alto riesgo y muy alto riesgo cardiovascular: ¿un reto posible?. Rev Clín Esp 206 9 (2006) 417-421
9. Pearson T., Ballantyne C., Sisk C., Shah A., Veltri E., and Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 99 (2007) 1706-1713
10. Pascual J.M., Rodilla E., and Sánchez C. Eficacia clínica de la ezetimiba y objetivos terapéuticos de colesterol unido a LDL. Clin Invest Arterioescl 18 (2006) 57-60
11. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflamation and cardiovascular disease: application to clinical and public heath practice: a statment for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
12. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction ecuation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1030 (1999) 461-470
13. Plaza Pérez I., Villar Álvarez F., Mata López P., Pérez Jiménez F., Maiques Galán G., Casasnovas Lenguas J.A., et al. Control de la colesterolemia en España, 2000: un instrumento para la prevención cardiovascular. Rev Clin Esp 200 (2000) 494-515
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
15. Whicher J.T., Ritchie R.F., Johnson A.M., Baudner S., Bienvenu J., Blirup-Jensen S., et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 40 (1994) 934-938
16. American Diabates Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 28 Suppl.1 (2005) S4-36
17. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al., For the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensisve versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
18. Ito M.K., Delucca G.M., and Aldridge M.A. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-relate events. J Cardiovasc Pharmacol Ther 6 (2001) 129-135
19. Stein E.A. Managing dyslipidemia in the high-risk patient. Am J Cardiol 89 5A (2002) 50C-57C
20. Rodilla E., Gómez-Belda A., Costa J.A., Aragó M., Miralles A., González C., et al. Variaciones de la proteína C reactiva inducidas por el tratamiento antihipertensivo e hipolipemiante. Med Clin (Barc) 125 (2005) 561-564
21. Kastelein J.J., Akdim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhoef A.F., et al. Simvastatin with or without ezetimibe in familiar hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
22. Rossebø A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., et al., SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008) 1343-1356
23. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am Heart J. 156:826- 32.
24. Pearson T.A., Ballantyne C.M., Veltri E., Shah A., Bird S., Lin J., et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 103 (2009) 369-374
25. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207